Non-tumor necrosis factor biological therapies for rheumatoid arthritis

APLAR Journal of Rheumatology

Volumn 8, Issue 2, 2005, Pages 77-83

  Chau, Lucia Shuk Yi ^a   Mok, Chi Chiu ^b   Choy, Ernest ^c  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^b TUEN MUN HOSPITAL   (Hong Kong)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Abatacept; Anakinra; Anti IL15; Anti IL6 receptor; Cytokines; Rituximab

Indexed keywords

ABATACEPT; AMG 714; CYCLOPHOSPHAMIDE; ETANERCEPT; INTERLEUKIN 15 ANTIBODY; INTERLEUKIN 6 ANTIBODY; METHOTREXATE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

BACTERIAL ARTHRITIS; BIOLOGICAL THERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DOSE RESPONSE; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; INJECTION SITE REACTION; KERATITIS; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TUBERCULOSIS;

EID: 27844537528     PISSN: 02190494     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2005.00133.x     Document Type: Review

References (35)

1. Feige U, Karbowski A, Rordorf-Adam C, et al. (1989) Arthritis induced by continuous infusion of hr-interleukin-1 alpha into the rabbit knee-joint. Int J Tissue React 11, 225-38.
2. Eastgate JA, Symons JA, Wood NC, et al. (1988) Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 2, 706-9.
3. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41, 2196-204.
4. Cohen S, Hurd E, Cush J, et al. (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46, 614-24.
5. Cohen SB, Moreland LW, Cush JJ, et al. (2004) A multicenter, double blind, randomized, placebo controlled trial of anakinra (Kineret), and recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63, 1062-8.
6. Jiang Y, Genant HK, Watt I, et al. (2000) A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 43, 1001-9.
7. Veith J, Wallis WJ, Modafferi D, et al. (2003) Anakinra safety experience: Infection results from a long-term safety study and postmarketing experience. Ann Rheum Dis 62, 191.
8. Schiff MH, DiVittorio G, Tesser J, et al. (2004) The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum 50, 1752-60.
9. Schiff MH, Bulpitt K, Weaver AA, et al. (2001) Safety of combination therapy with anakinra and etanercept in patients with rheumatoid arthritis. Arthritis Rheum 44, S79.
10. Genovese M, Cohen S, Moreland L, et al. (2004) Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50, 1412-9.
11. National Institute of Clinical Excellence. Full guidance: anakinra for rheumatoid arthritis. Technology appraisal Nov 2003. http://www.nice.org.uk/pdf/ TA072guidance.pdf.
12. Schiff MH, Keystone EC, Gibofsky A, et al. (2003) An evaluation of the use of anakinra by rheumatoid arthritis patients previously treated with a TNF inhibitor. Ann Rheum Dis 62, 186.
13. Verbsky JW, White AJ (2004) Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 31, 2071-5.
14. Irigoyen PI, Olson J, Hom C, et al. (2004) Treatment of Systemic Onset Juvenile Rheumatoid Arthritis with anakinra. Arthritis Rheum 50, S437.
15. Ilowite NT, Porras O, Reiff A, et al. (2003) A twelve-week open label safety and efficacy study of anakinra (Kineret) in juvenile rheumatoid arthritis. Ann Rheum Dis 62, 87.
16. Dasgupta B, Corkill M, Kirkham B, et al. (1992) Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arhtritis. J Rheumatol 19, 22-5.
17. Kotake S, Sato K, Kim KJ, et al. (1996) Interleukin 6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 11, 88-95.
18. Boe A, Baiocchi M, Carbonatto M, et al. (1999) Interleukin 6 knockout mice are resistant to antigen-induced experimental arthritis. Eur Cytokine Netw 11, 1057-64.
19. Takagi N, Mihara M, Moriya Y, et al. (1998) Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 41, 2117-21.
20. Mihara M, Kotah M, Nishimoto N, et al. (2001) Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin Immunol 98, 319-26.
21. Wendling D, Racadot E, Wijdenses J (1993) Treatment of severe rheumatoid arthritis by anti-interleukin-6 monoclonal antibody. J Rheumatol 20, 259-62.
22. Choy EH, Isenberg DA, Garrood T, et al. (2002) Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomised, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46, 3143-50.
23. Maini RN, Taylor PC, Pavelka K, et al. (2003) Efficacy of IL6 receptor antagonist MRA in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA). Arthritis Rheum 48, S652.
24. Nishimoto N, Yoshizaki K, Miyasaka N, et al. (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 50, 1761-9.
25. Ruchatz H, Leung BP, Wei XQ, et al. (1998) Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J Immunol 160, 5654-60.
26. Ferrari-Lacraz S, Zanelli E, Neuberg M, et al. (2004) Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J Immunol 173, 5818-26.
27. Baslund B, Tvede N, Danneskiold-Samsoe B, et al. (2003) A novel human monoclonal antibody against IL-15 (HuMax-15) in patients with active rheumatoid arthritis (RA): results of a double-blind, placebo-controlled phase I/II trial. Arthritis Rheum 48, S653.
28. McInnes I, Martin R, Zimmerman-Gorska I, et al. (2004) Safety and efficacy of a human monoclonal antibody to IL15 (AMG 714) in patients with rheumatoid arthritis (RA): results from a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 50, S241.
29. Webb LMC, Walmesley MJ, Feldmann M (1996) Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol 26, 2320-8.
30. Moreland LW, Alten R, Van den Bosch F, et al. (2002) Costimulatory blockade in patients with rheumatoid arthritis. A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4 and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46, 1470-9.
31. Kremer JM, Westhovens R, Leon M, et al. (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4-Ig. N Eng J Med 349, 1907-15.
32. Edwards JCW, Cambridge G (2001) Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 41, 205-11.
33. De Vita S, Zaja F, Sacco S, et al. (2002) Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis. Arthritis Rheum 46, 2029-33.
34. Edwards JCW, Szczepanski L, Szechiriski J, et al. (2004) Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Eng J Med 350, 2572-81.
35. Edwards JCW, Leandro MJ, Cambridge G (2005) B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am 30, 393-403.